2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.046 Aida Myftiu NACLC Abstract

PP01.046 Aida Myftiu NACLC Abstract

Pdf Summary

The 2023 North America Conference on Lung Cancer (NACLC) will take place on December 1-3 in Chicago, Illinois, USA. The conference will feature presentations on various topics related to lung cancer, including real-world rebiopsy and biomarker retesting rates among patients with non-small cell lung cancer (NSCLC) in the United States.<br /><br />The proposed title of one presentation is "word count 20/20: Real-World Rebiopsy and Biomarker Retesting Rates Among Patients With Non-Small Cell Lung Cancer Across Patient Demographics in the United States." The authors of the presentation are Charu Aggarwal, Qingqing Xu, Sophia Ng, Rajesh Kamalakar, Samuel Crawford, Sue Beruti, Aida Myftiu, and Mary Beth Beasley.<br /><br />The study, funded by AbbVie, aims to analyze the patterns of rebiopsy and retesting of actionable genetic alterations in patients with NSCLC across different lines of therapy. The researchers utilized the ConcertAI Patient360 database to retrospectively assess biomarker testing patterns and biopsy rates among adults with nonsquamous NSCLC from 2017 to 2022. The analysis was stratified by race/ethnicity, region, age, and sex.<br /><br />The results showed that among the 4,528 patients studied, there were racial and gender differences in rebiopsy and retesting rates. Patients with an actionable mutation were more likely to undergo additional diagnostic procedures. However, patients with EGFR wild-type status, Black patients, and male patients had lower rates of rebiopsy in the second line of therapy compared to other groups. Male patients also had lower rates of rebiopsy and retesting compared to female patients in the second line of therapy.<br /><br />The authors conclude that standardization of biomarker testing in later lines of therapy is needed to ensure optimal and equitable treatment decisions for all patients with NSCLC.<br /><br />Keywords: NSCLC, biomarker, retesting, rebiopsy

Keywords

NSCLC

biomarker

retesting

rebiopsy

lung cancer

conference

patient demographics

genetic alterations

diagnostic procedures

treatment decisions